# Validation Evidence — Release Recommendation

**See `PHARMAGPT_v1.0_PHASE_F_RELEASE_CERTIFICATION.md` (repo root) for the full, authoritative Go/No-Go analysis.** This file is a one-paragraph pointer, not a duplicate.

**Summary:** Phase F fixed and verified all six Critical findings from Phase E that were reachable by a code-only session (C2-C7), using real evidence — 14 new passing automated tests, a schema migration, and direct code re-reads — and disclosed rather than fabricated verification for anything it could not prove. One Critical finding (Company Administration / Assume Company Context, non-functional due to live database GRANTs) remains open — it is an operational database action outside what this session could execute, not a code defect. The recommendation is **NO-GO**, unchanged in direction from Phase E but substantially improved in position, with a narrow, well-defined path to GO (see the certification document's final section).
